AGL 32.85 Decreased By ▼ -0.25 (-0.76%)
AIRLINK 127.01 Decreased By ▼ -2.39 (-1.85%)
BOP 5.01 Decreased By ▼ -0.06 (-1.18%)
CNERGY 3.75 Decreased By ▼ -0.09 (-2.34%)
DCL 7.64 Decreased By ▼ -0.37 (-4.62%)
DFML 48.35 Increased By ▲ 0.31 (0.65%)
DGKC 73.00 Decreased By ▼ -1.29 (-1.74%)
FCCL 25.16 Decreased By ▼ -0.09 (-0.36%)
FFBL 48.10 Increased By ▲ 1.54 (3.31%)
FFL 8.50 Decreased By ▼ -0.21 (-2.41%)
HUBC 124.20 Increased By ▲ 1.00 (0.81%)
HUMNL 9.62 Decreased By ▼ -0.38 (-3.8%)
KEL 3.66 Decreased By ▼ -0.17 (-4.44%)
KOSM 8.45 Increased By ▲ 0.20 (2.42%)
MLCF 32.69 Increased By ▲ 0.19 (0.58%)
NBP 57.52 Decreased By ▼ -2.51 (-4.18%)
OGDC 144.00 Increased By ▲ 0.70 (0.49%)
PAEL 25.00 Decreased By ▼ -0.45 (-1.77%)
PIBTL 5.68 Decreased By ▼ -0.16 (-2.74%)
PPL 108.24 Increased By ▲ 0.44 (0.41%)
PRL 23.70 Decreased By ▼ -0.41 (-1.7%)
PTC 11.55 Decreased By ▼ -0.01 (-0.09%)
SEARL 57.50 Decreased By ▼ -0.70 (-1.2%)
TELE 7.10 Decreased By ▼ -0.15 (-2.07%)
TOMCL 39.60 Decreased By ▼ -1.26 (-3.08%)
TPLP 7.18 Decreased By ▼ -0.22 (-2.97%)
TREET 14.55 Decreased By ▼ -0.34 (-2.28%)
TRG 52.62 Decreased By ▼ -2.13 (-3.89%)
UNITY 25.50 Decreased By ▼ -0.70 (-2.67%)
WTL 1.20 Decreased By ▼ -0.03 (-2.44%)
BR100 8,530 Decreased By -31.4 (-0.37%)
BR30 25,672 Decreased By -164.1 (-0.64%)
KSE100 81,292 Decreased By -365.8 (-0.45%)
KSE30 25,810 Decreased By -64.8 (-0.25%)

Bangladesh's leading drug maker Beximco Pharmaceuticals Limited (BPL) said on Saturday it has raised 6.5 million pounds through the issue of 8,175,750 further global depository receipts (GDRs) on the London Stock Exchange, each representing one ordinary share of 10 taka each at an issue price of 80 pence per GDR.
The newly issued GDRs were admitted for trading on June 1 on the Alternative Investment Market (AIM) of the London Stock Exchange, a BPL statement said.
"We have been delighted by the interest in Beximco from international investors since the company's IPO in London last year and we are grateful to them for their continuing support in this fundraising as we develop the infrastructure of our business and invest in its growth," said Nazmul Hassan, Chief Executive Officer of Beximco Pharmaceuticals said in the statement.

Copyright Reuters, 2006

Comments

Comments are closed.